Rebekah Rittberg

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Topics

Ejection Fraction

Brain Metastases

Small Cell Lung Cancer

Top Venues

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current oncology (Toronto, Ont.) 30 (6) (2023)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami, Cheryl Ho
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization. Current oncology (Toronto, Ont.) 29 (12) (2022)
Lauren Jones, Rebekah Rittberg, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina K Wong, Zamzam Al-Hashami, Ying Wang, Cheryl Ho
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing. Current oncology (Toronto, Ont.) 29 (11) (2022)
Rebekah Rittberg, Craig Harlos, Heidi Rothenmund, Anirban Das, Uri Tabori, Namita Sinha, Harminder Singh, Bernie Chodirker, Christina A Kim
Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report-Usage of Immune Checkpoint Inhibition in CMMRD. Current oncology (Toronto, Ont.) 28 (1) (2021)
Rebekah Rittberg, Anmol Mann, Danielle Desautels, Craig C Earle, Sri Navaratnam, Marshall Pitz
Canadian Cancer Centre Response to COVID-19 Pandemic: A National and Provincial Response. Current oncology (Toronto, Ont.) 28 (1) (2020)